

Lonza Announces Results of the 2021 Annual General Meeting – All Motions Proposed by Board of Directors Accepted

- 47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital
- Shareholders re-elected all existing members of the Board of Directors
- Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year
- A dividend of CHF 3.00 per share will be paid out starting from 12 May 2021

Basel, Switzerland, 6 May 2021 – Today, Lonza Group Ltd hosted its Annual General Meeting, led by the Chairman of the Board of Directors, Albert M. Baehny. Due to the ongoing COVID-19 pandemic, no shareholders were admitted to attend the Annual General Meeting in person. Lonza had previously recommended that shareholders delegate their votes to the independent proxy on 25 March 2021. The independent proxy represented 100% of the 47,080,080 votes represented at the Annual General Meeting.

The Board members standing for re-election (Albert M. Baehny, Werner Bauer, Dorothee Deuring, Angelica Kohlmann, Christoph Mäder, Barbara Richmond, Jürgen Steinemann and Olivier Verscheure) were all elected for a further term in office of one year.

The Annual General Meeting re-elected Albert M. Baehny as Chairman of the Board of Directors for a term in office of one year. The shareholders also re-elected Angelica Kohlmann, Christoph Mäder and Jürgen Steinemann as the three acting members of the Nomination and Compensation Committee.

The shareholders supported all other motions proposed by the Board of Directors, including among others the acceptance of the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee. The shareholders also approved the renewal of the authorized share capital.

A dividend of CHF 3.00 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out starting from 12 May 2021. Fifty percent of this dividend will be paid out of the capital contribution reserve and will be free from Swiss withholding tax.

For further information please see the short-form minutes of the 2021 Lonza Annual General Meeting under the following [link](#).

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com.

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.